Stock Events

Stock Events

Baudax Bio 

$0.02
65
+$0+7.39% Thursday 20:53

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

23AugExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
Q2 2024
-98.8
-63.95
-29.1
5.75
Expected EPS
-0.09
Actual EPS
N/A

Financials

-4,633.18%Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
1.27MRevenue
-58.8MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BXRX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pacira BioSciences
PCRX
Mkt Cap958.08M
Pacira Biosciences focuses on non-opioid pain management, directly competing with Baudax Bio's non-opioid analgesic offerings.
Trevena
TRVN
Mkt Cap9,501
Trevena, Inc. develops novel medicines for pain management, including oliceridine, a competitor to Baudax Bio's analgesic products.
Heron Therapeutics
HRTX
Mkt Cap150.68M
Heron Therapeutics focuses on improving the therapeutic profile of pain management products, directly competing with Baudax Bio's portfolio.
Nektar Therapeutics
NKTR
Mkt Cap2.21B
Nektar Therapeutics works on pain management therapies that could compete with Baudax Bio's non-opioid analgesic solutions.
Collegium Pharmaceutical
COLL
Mkt Cap1.03B
Collegium Pharmaceutical offers pain management solutions that could be seen as alternatives to Baudax Bio's products.
Evolus
EOLS
Mkt Cap270.65M
Evolus competes in the broader pharmaceutical market, indirectly competing with Baudax Bio's focus on pain management through its aesthetic medicine portfolio.
Supernus Pharmaceuticals
SUPN
Mkt Cap2.91B
Supernus Pharmaceuticals has a focus on central nervous system diseases but also competes in the pain management market, overlapping with Baudax Bio's interests.

About

Health Technology
Pharmaceuticals: Major
Manufacturing
Medicinal and Botanical Manufacturing
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.
Show more...
CEO
Employees
9
Country
US
ISIN
US07160F4046

Listings

OTC Link
US
BXRXQ

0 Comments

Share your thoughts

FAQ

What is Baudax Bio stock price today?▼
The current price of BXRX is $0.02 USD — it has increased by +7.39% in the past 24 hours. Watch Baudax Bio stock price performance more closely on the chart.
What is Baudax Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Baudax Bio stocks are traded under the ticker BXRX.
What is Baudax Bio revenue for the last year?▼
Baudax Bio revenue for the last year amounts to 1.27M USD.
What is Baudax Bio net income for the last year?▼
BXRX net income for the last year is -58.8M USD.
How many employees does Baudax Bio have?▼
As of April 09, 2026, the company has 9 employees.
In which sector is Baudax Bio located?▼
Baudax Bio operates in the Manufacturing sector.
When did Baudax Bio complete a stock split?▼
The last stock split for Baudax Bio was on December 01, 2022 with a ratio of 1:40.